ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Period	TotalRevenue
2015-12-31	$7.18M
2016-12-31	$10.66M
2017-12-31	$22.76M
2018-12-31	$16.99M
2019-12-31	$29.35M
2020-12-31	$42.22M
2021-12-31	$80.94M
2022-12-31	$154.08M
2023-12-31	$258.21M
2024-12-31	$426.45M

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ADMA	$9.88	+6.64%	2.99M
3
4
5

ADMA Biologics Inc (ADMA) Revenue History

Revenue Data

Get ADMA Biologics Inc Data in Excel

More ADMA Financial Data